Fas ligand expression in BRCA1-associated hereditary breast carcinoma clearly differs from that in sporadic breast carcinoma Yasuhiro ItoShinzaburo NoguchiNariaki Matsuura OriginalPaper Pages: 95 - 100
Metastatic bone pain palliation with 89‐Sr and 186‐Re‐HEDP in breast cancer patients Rosa SciutoAnna FestaCarlo L. Maini OriginalPaper Pages: 101 - 109
Oncostatin M–induced growth inhibition and morphological changes of MDA‐MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway Cong LiThomas E. AhlbornJingwen Liu OriginalPaper Pages: 111 - 121
Are medical oncologists biased in their treatment of the large woman with breast cancer? Yolanda MadarnasCarol A. SawkaGeorg A. Bjarnason OriginalPaper Pages: 123 - 133
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women Patrizia QuerzoliGiuseppe AlbonicoItalo Nenci OriginalPaper Pages: 135 - 142
Generation of reactive oxygen species by xanthine derivatives in MDA‐MB‐231 human breast cancer cells T.L. CrumptonF.J. SeidlerT.A. Slotkin OriginalPaper Pages: 143 - 146
Methyl‐substituted diindolylmethanes as inhibitors of estrogen‐induced growth of T47D cells and mammary tumors in rats Andrew McDougalMona Sethi GuptaStephen H. Safe OriginalPaper Pages: 147 - 157
Clinical significance of vascular endothelial growth factor‐C (VEGF‐C) in breast cancer Junko KinoshitaKaoru KitamuraKeizo Sugimachi OriginalPaper Pages: 159 - 164
Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors Kazuyuki YazawaMinoru FujimoriShun’ichiro Taniguchi OriginalPaper Pages: 165 - 170